BRPI0916847A2 - preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto. - Google Patents

preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto.

Info

Publication number
BRPI0916847A2
BRPI0916847A2 BRPI0916847A BRPI0916847A BRPI0916847A2 BR PI0916847 A2 BRPI0916847 A2 BR PI0916847A2 BR PI0916847 A BRPI0916847 A BR PI0916847A BR PI0916847 A BRPI0916847 A BR PI0916847A BR PI0916847 A2 BRPI0916847 A2 BR PI0916847A2
Authority
BR
Brazil
Prior art keywords
compound
stabilizing
improving
methods
solid preparation
Prior art date
Application number
BRPI0916847A
Other languages
English (en)
Inventor
Junya Nomura
Yutaka Tanoue
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916847(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0916847A2 publication Critical patent/BRPI0916847A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0916847A 2008-07-31 2009-07-29 preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto. BRPI0916847A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8520108P 2008-07-31 2008-07-31
US8562708P 2008-08-01 2008-08-01
PCT/JP2009/063833 WO2010013835A2 (en) 2008-07-31 2009-07-29 Solid pharmaceutical composition

Publications (1)

Publication Number Publication Date
BRPI0916847A2 true BRPI0916847A2 (pt) 2016-02-10

Family

ID=41610805

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916847A BRPI0916847A2 (pt) 2008-07-31 2009-07-29 preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto.

Country Status (26)

Country Link
US (1) US9169238B2 (pt)
EP (1) EP2310385B1 (pt)
JP (1) JP5635491B2 (pt)
KR (1) KR20110038145A (pt)
CN (1) CN102164918B (pt)
AR (1) AR072883A1 (pt)
AU (1) AU2009277455A1 (pt)
BR (1) BRPI0916847A2 (pt)
CA (1) CA2732018C (pt)
CL (1) CL2011000187A1 (pt)
CO (1) CO6341633A2 (pt)
CR (1) CR20110111A (pt)
DO (1) DOP2011000032A (pt)
EA (1) EA201170273A1 (pt)
EC (1) ECSP11010856A (pt)
GE (1) GEP20146062B (pt)
IL (1) IL210819A0 (pt)
MA (1) MA32553B1 (pt)
MX (1) MX2011001150A (pt)
NZ (1) NZ590948A (pt)
PE (1) PE20110551A1 (pt)
PT (1) PT2310385T (pt)
TW (1) TW201008915A (pt)
UY (1) UY32017A (pt)
WO (1) WO2010013835A2 (pt)
ZA (1) ZA201100871B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
CA2882730C (en) * 2012-08-22 2019-12-31 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP6935301B2 (ja) * 2016-11-18 2021-09-15 花王株式会社 モノハロゲノアミン製造用被覆粒子群
IN202021028444A (pt) * 2020-07-03 2022-01-28

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) * 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
EP1258254A4 (en) 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
JP2001294524A (ja) 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd アセトアミノフェン配合内服固形製剤
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
JP4365106B2 (ja) * 2001-05-25 2009-11-18 エスエス製薬株式会社 医薬配合剤
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
WO2005014043A1 (en) 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7625940B2 (en) * 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
US20080004320A1 (en) * 2004-09-06 2008-01-03 Kowa Co., Ltd. Remedy for Glomerular Disease
US20070049636A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
KR20070097511A (ko) * 2004-12-17 2007-10-04 베링거 인겔하임 인터내셔날 게엠베하 텔미사르탄 및 하이드로클로로티아지드를 포함하는 배합치료
KR20070116648A (ko) * 2005-03-30 2007-12-10 다케다 야쿠힌 고교 가부시키가이샤 벤즈이미다졸 유도체 및 안지오텐신 ⅱ 길항제로서의 용도
EP1885694A2 (en) 2005-05-13 2008-02-13 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
GEP20125420B (en) * 2006-08-10 2012-03-26 Takeda Pharmaceutical Solid pharmaceutical composition comprising benzimidazole compound
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
PE20130210A1 (es) 2007-03-28 2013-03-11 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
KR20100046216A (ko) 2007-08-01 2010-05-06 테바 파마슈티컬 인더스트리즈 리미티드 칸데사르탄의 약학 조성물
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
ZA201100871B (en) 2012-05-30
GEP20146062B (en) 2014-03-25
JP5635491B2 (ja) 2014-12-03
WO2010013835A2 (en) 2010-02-04
JP2011529444A (ja) 2011-12-08
CN102164918A (zh) 2011-08-24
WO2010013835A3 (en) 2010-06-10
CN102164918B (zh) 2014-05-07
CL2011000187A1 (es) 2011-06-24
EP2310385B1 (en) 2017-06-07
CO6341633A2 (es) 2011-11-21
TW201008915A (en) 2010-03-01
ECSP11010856A (es) 2011-03-31
NZ590948A (en) 2012-06-29
CA2732018C (en) 2017-07-04
EA201170273A1 (ru) 2011-08-30
IL210819A0 (en) 2011-04-28
KR20110038145A (ko) 2011-04-13
DOP2011000032A (es) 2011-02-28
US20110123615A1 (en) 2011-05-26
UY32017A (es) 2010-02-26
US9169238B2 (en) 2015-10-27
MX2011001150A (es) 2011-03-29
AU2009277455A1 (en) 2010-02-04
MA32553B1 (fr) 2011-08-01
EP2310385A2 (en) 2011-04-20
AR072883A1 (es) 2010-09-29
PE20110551A1 (es) 2011-09-02
CR20110111A (es) 2011-04-28
CA2732018A1 (en) 2010-02-04
PT2310385T (pt) 2017-09-11

Similar Documents

Publication Publication Date Title
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0911898A2 (pt) processo para preparar compostos, e, composto.
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BRPI0912716A2 (pt) composto.
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0905707A2 (pt) Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0914182A2 (pt) composto, e, composição farmacêutica
BRPI0916847A2 (pt) preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0817010A2 (pt) Processo de preparação de um composto p-hidroximandélico eventualmente substituído e derivado e de um aldeído 4-hidroxiaromático.
BR112012003775A2 (pt) processo para a preparação de um composto, composto e composição
BRPI0914924A2 (pt) processo para preparar aminobifenilas, e, composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]